Nav: Home

Bench to beside study of a targetable enzyme controlling aggressive prostate cancer

July 02, 2019

PHILADELPHIA -- Prostate cancer represents a major health challenge and there is currently no effective treatment once it has advanced to the aggressive, metastatic stage. A new has revealed a key cellular mechanism that contributes to aggressive prostate cancer, and supporting a new clinical trial. The study was published in the journal Clinical Cancer Research.

The research led by investigators at the Sidney Kimmel Cancer Center - Jefferson Health (SKCC) and their collaborators at Memorial Sloan Kettering Cancer Center, the University of California, San Francisco, and Celgene Corporation, focused on an enzyme called DNA-PK (DNA-dependent protein kinase), a pivotal component of the cellular machinery that controls both DNA repair and influences gene expression. The work was orchestrated by the laboratory of Karen E. Knudsen, PhD, EVP of Oncology Services and Enterprise Director of SKCC.

Previous studies showed that DNA-PK is excessively active in metastatic prostate cancer and that its hyper-activation is associated with a poor outcome in prostate cancer patients. "Our study further elucidates the functions of DNA-PK and identifies this protein as a master regulator of gene networks that promote aggressive cancer behaviors," says lead author Emanuela Dylgjeri.

A companion study in the same issue led by the laboratory of Felix Feng, MD, in collaboration with the Kundsen laboratory, identified DNA-PK as the most significantly associated kinase with metastatic progression of the disease. In an effort to understand how DNA-PK induces poor outcomes, the investigators found that DNA-PK modulates the expression of gene networks controlling a variety of important cancer-related cellular events, including a developmental process termed the epithelial-mesenchymal transition, the immune response, metabolic pathways (Dylgjeri et al.) and Wnt signaling (Kothari et al.).

The new findings suggest that targeting DNA-PK might allow the development of effective strategies to prevent or treat aggressive, late-stage prostate cancer. Data from the studies was used to develop a clinical trial combining standard-of-care with a first-in-man DNA-PK inhibitor. Early results of the trial have been promising, and the researchers have demonstrated in a laboratory setting that the combined approach is more effective than either single treatment in eliciting anti-tumor effects. The clinical trial is still underway and has now entered the expansion phase of testing.

The newly published studies are focused on translating basic science findings from the laboratory to the clinic, but the investigators also plan to take the lessons learned in the clinic back to the laboratory. The results of the clinical trial will offer important clues and raise new questions that will guide the design of new experiments, with the ultimate goal of understanding how DNA-PK regulates specific cellular pathways to promote more aggressive cancer behavior. These studies in turn will aid in the development of more accurate genetic tests to detect advanced prostate cancer, identify the most appropriate course of treatment for individual patients, and predict treatment outcomes. Team leader Dr. Karen Knudsen envisions long-term practical outcomes of this research, saying "it is our hope to use the information gained by these studies to understand which prostate cancer patients might benefit the most from combination treatments with a DNA-PK inhibitor drug".
Article references: Emanuela Dylgjeri, Christopher McNair, Jonathan F. Goodwin, Heather K. Raymon, Peter A. McCue, Ayesha A. Shafi, Benjamin E. Leiby, Renée de Leeuw, Vishal Kothari, Jennifer J. McCann, Amy C. Mandigo, Saswati N. Chand, Matthew J. Schiewer, Lucas J. Brand, Irina Vasilevskaya, Nicolas Gordon, Talya S. Laufer, Leonard G. Gomella, Costas D. Lallas, Edouard J. Trabulsi, Felix Y. Feng, Ellen H. Filvaroff, Kristin Hege, Dana Rathkopf and Karen E. Knudsen, "Pleiotropic impact of DNA-PK in cancer and implications for therapeutic strategies," Clinical Cancer Research, DOI: 10.1158/1078-0432.CCR-18-2207, 2019.

Vishal Kothari, Jonathan F Goodwin, Shuang G Zhao, Justin M Drake, Yi Yin, S. Laura Chang, Joseph R Evans, Kari Wilder-Romans, Kristina Gabbara, Emanuela Dylgjeri, Jonathan Chou, Grace Sun, Scott A. Tomlins, Rohit Mehra, Kristen Hege, Ellen H. Filvaroff, Edward M. Schaeffer, R. Jeffrey Karnes, David A Quigley, Dana Rathkopf, Housheng H. He, Corey Speers, Daniel E. Spratt, Luke A Gilbert, Alan Ashworth, Arul M. Chinnaiyan, Ganesh V Raj, Karen E Knudsen and Felix Y. Feng, "DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway," Clinical Cancer Research, DOI: 10.1158/1078-0432.CCR-18-2387, 2019.

Media Contact: Lauren Riley, 215-503-4277, OR Edyta Zielinska, 215-955-7359,

Thomas Jefferson University

Related Clinical Trial Articles:

Landmark clinical trial to help juvenile idiopathic arthritis sufferers
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.
Clinical trial for new innovative osteoarthritis drug
The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis.
New malaria vaccine effective in clinical trial
University of Tuebingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.
Clinical trial of infection detecting bandages begins
A clinical trial of a smart bandage which changes color when it detects infections is beginning using samples from burns patients from four UK hospitals.
First human clinical trial for nicotinamide riboside
In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.
Tapping into behavioral economics to boost clinical trial participation
Behavioral economics may offer a powerful tool for improving patient enrollment in clinical trials, argue Eric VanEpps, Kevin Volpp, and Scott Halpern in this Focus.
Clinical trial examines treatment of complicated grief
A new study reports on the results of a randomized clinical trial that looked at whether the antidepressant citalopram would enhance complicated grief treatment psychotherapy, and if citalopram would be efficacious without it in an article published online by JAMA Psychiatry.
Crossref Publishers deliver win for clinical trial openness
At the click of a button, health professionals and researchers will now be able to view all of the clinical trials referenced in the paper they are reading, and any related publications such as the protocol, statistical analysis plan, and results articles.
New database for sharing MS clinical trial data
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort of the National MS Society and Critical Path Institute (C-Path), is launching a database, accessible to qualified researchers, containing trial data from nearly 2,500 patients from the placebo arms of nine MS clinical trials.
Clinical trial for experimental Ebola drug publishes results
Results of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 published in PLOS Medicine.

Related Clinical Trial Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.